Gilead, Assembly Bio partner to develop medicines for serious viral diseases
The partnership will initially focus on Assembly Bio’s next-gen core inhibitor ABI-4334, intended for HBV, long-acting helicase-primase inhibitor…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Oct 23
The partnership will initially focus on Assembly Bio’s next-gen core inhibitor ABI-4334, intended for HBV, long-acting helicase-primase inhibitor…
18 Oct 23
The partnership will combine Monte Rosa’s highly differentiated QuEEN discovery engine with Roche’s expertise in providing transformative therapies…
17 Oct 23
The deal, builds on the previously announced deal and licence agreement in 2022, is intended to combine LCB’s…
13 Oct 23
Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig)…
12 Oct 23
Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding…
11 Oct 23
Under the agreement, the three firms will advance SakuLab-Tsukuba, an open innovation hub launched by Astellas, and expedite…
10 Oct 23
The partnership will substantially enhance the accessibility of Shingrix in China, as it involves joint promotion to healthcare…
10 Oct 23
Oregovomab is a murine monoclonal antibody
06 Oct 23
Bayer will have the option to license antibodies discovered under the collaboration
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…